Call for Abstract
15th International Pharmaceutical Microbiology and Biotechnology Conferenc, will be organized around the theme “Explore the development of research in the field of Microbiology and Biotechnology”
Pharmaceutical Microbiology 2017 is comprised of 27 tracks and 661 sessions designed to offer comprehensive sessions that address current issues in Pharmaceutical Microbiology 2017.
Submit your abstract to any of the mentioned tracks. All related abstracts are accepted.
Register now for the conference by choosing an appropriate package suitable to you.
Pharmaceutical Microbiology deals with the study of microorganisms that is concerned within the manufacture of prescribed drugs e.g. minimizing the quantity of microorganisms in an exceedingly method setting, excluding microorganisms and microorganism by-products like exotoxin and endotoxin from water and alternative beginning materials, and making certain the finished pharmaceutical product is sterile. Alternative aspects of pharmaceutical biological science embrace the analysis and development of anti-infective agents, the employment of microorganisms to sight agent and malignant neoplastic disease activity in prospective medication, and therefore the use of microorganisms within the manufacture of pharmaceutical product like endocrine and human human growth hormone.
The microbiology market has significantly grown in recent years as the demand from end user industries increases. With this expansion and increased demand comes hurdles for the industry.
- Track 1-1New trends in Pharmaceutical Microbiology
- Track 1-2Future approaches
- Track 1-3Metabolic engineering
- Track 1-4Fermenters and Fermentation
- Track 1-5Microbes in clinical perspective
- Track 1-6Microbial Nanotechnologies
- Track 1-7Microbial monitoring for biological drugs
- Track 1-8Real-time waterborne microbial detection
- Track 1-9New trends in detection of micro organisms
- Track 1-10 Microbial chemotherapy
- Track 1-11Biofilms
- Track 1-12Trends in biotechnology
- Track 1-13 Biopharmaceuticals
- Track 1-14Microbial fuel cells
- Track 1-15Agricultural Microbiology
- Track 1-16Beneficial micro organism
- Track 1-17Innovations
- Track 1-18Industrial Microbiology
- Track 1-19Pharmaceutical microbiology and Drug safety
Microbiology is the study of microscopic organisms, such as bacteria, viruses, archaea, fungi and protozoa. This discipline includes fundamental research on the biochemistry, physiology, cell biology, ecology, evolution and clinical aspects of microorganisms, including the host response to these agents.
Eukaryotic micro-organisms possess membrane-bound cell organelles and include fungi and protists, whereas prokaryotic organisms—all of which are microorganisms—are conventionally classified as lacking membrane-bound organelles and include eubacteria and archaebacteria. Microbiologists traditionally relied on culture, staining, and microscopy. However, less than 1% of the microorganisms present in common environments can be cultured in isolation using current means. Microbiologists often rely on extraction or detection of nucleic acid, either DNA or RNA sequences.
Viruses have been variably classified as organisms, as they have been considered either as very simple microorganisms or very complex molecules. Prions, never considered microorganisms, have been investigated by virologists, however, as the clinical effects traced to them were originally presumed due to chronic viral infections, and virologists took search—discovering "infectious proteins".
- Track 2-1Bacteriology
- Track 2-2Nano microbiology
- Track 2-3Exo microbiology
- Track 2-4Predictive microbiology
- Track 2-5Applied microbiology
- Track 2-6Water Microbiology & Novel Technologies
- Track 2-7Medical microbiology
- Track 2-8Industrial microbiology
- Track 2-9Microbial biotechnology
- Track 2-10Food microbiology
- Track 2-11Agricultural microbiology
- Track 2-12Veterinary microbiology
- Track 2-13Environmental microbiology
- Track 2-14Aeromicrobiology
- Track 2-15Molecular microbiology
- Track 2-16Systems microbiology
- Track 2-17Generation microbiology
- Track 2-18Mycology
- Track 2-19Protozoology
- Track 2-20Phycology or algology
- Track 2-21Parasitology
- Track 2-22Immunology
- Track 2-23Virology
- Track 2-24Nematology
- Track 2-25Microbial cytology
- Track 2-26Microbial physiology
- Track 2-27Microbial ecology
- Track 2-28Microbial genetics
- Track 2-29Cellular microbiology
- Track 2-30Evolutionary microbiology
- Track 2-31Microorganisms
Biotechnology is the use of living systems and organisms to develop or make products, or "any technological application that uses biological systems, living organisms, or derivatives thereof, to make or modify products or processes for specific use". Depending on the tools and applications, it often overlaps with the (related) fields of bioengineering, biomedical engineering, biomanufacturing, molecular engineering, etc.
For thousands of years, humankind has used biotechnology in agriculture, food production, and medicine. The term is largely believed to have been coined in 1919 by Hungarian engineer Károly Ereky. In the late 20th and early 21st centuries, biotechnology has expanded to include new and diverse sciences such as genomics, recombinant gene techniques, applied immunology, and development of pharmaceutical therapies and diagnostic tests.
- Track 3-1Bioinformatics
- Track 3-2Current Scenario in Biotechnology
- Track 3-3Biotechnology and its Applications
- Track 3-4Algal Biotechnology
- Track 3-5Biomass and Bioenergy
- Track 3-6Bioremediation and Biodegradation
- Track 3-7Environmental Biotechnology
- Track 3-8Plant and Agriculture Biotechnology
- Track 3-9Reproductive Biotechnology
- Track 3-10Nanobiotechnology
- Track 3-11Pharmaceutical Biotechnology
- Track 3-12Systems and Synthetic Biotechnology
- Track 3-13Genetic Engineering and rDNA Technology
- Track 3-14Biotechnology in Medical and Healthcare
- Track 3-15Microbial Biotechnology
- Track 3-16Industrial Biotechnology
- Track 3-17Biorobotics
- Track 3-18Bioprocess engineering
- Track 3-19Biotechnology and Market Scope
Antibiotics are a type of antimicrobials that are used in treatment and prevention of bacterial infections. They may kill or inhibit the growth of bacteria. Many antibiotics are also effective against protozoans and fungi; some are toxic to humans and animals also, even when given in therapeutic dosage. Antibiotics are not effective against viruses such as common cold or influenza, and may be harmful when taken inappropriately. Physicians must ensure the patient has a bacterial infection before prescribing antibiotics.
The golden age of the discovery of antibiotics from 1940 to the early 1970s marked the beginning of a new era in human and animal health and the dramatic increase in human life expectancy. Indeed, the possibility of eradicating infectious diseases seemed possible. However, it soon became apparent that the microorganisms would not be defeated so easily. Their weapon: resistance to antibiotics. Today, resistance to microbial antibiotics rapidly depletes our supply of effective compounds and the possibility of a global public health disaster seems likely. The urgency of this situation has spawned a plethora of new multidisciplinary research initiatives in search of new antibiotics and other antimicrobial agents.
- Track 4-1Antibiotics, invention and innovation
- Track 4-2Clinical Trials of Antibiotics
- Track 4-3Modern Antibiotics for Various Diseases and Infections
- Track 4-4Antibiotic Regulatory Affairs
- Track 4-5Advances in Antibiotic Treatment
- Track 4-6Antibiotics for Cancer
- Track 4-7Antibiotics: In Pregnancy and Lactation
- Track 4-8Antibiotics for Diabetes
- Track 4-9Antibiotics: Market Analysis & Business Opportunities
- Track 4-10Antibiotic Prophylaxis
- Track 4-11Micro Organisms in Recent Drug Discovery
- Track 4-12Different Types of Antibiotics and their Applications
- Track 4-13Antibiotics and Mechanism of Action
- Track 4-14Encouraging Antibiotic Innovation
- Track 4-15Antibiotic pipeline
- Track 4-16Molecular Microbiology
- Track 4-17New class of antibiotics discovered
- Track 4-18 A Plan For New Antibiotics
- Track 4-19The Emergence of Antimicrobial Resistance
- Track 4-20Antibiotic Resistance: Opportunities and Challenges
- Track 4-21Drug Discovery and Novel Delivery Technologies
- Track 4-22Antibiotics for Emerging and Re-emerging Diseases
- Track 4-23Antibiotics in Different Industries
The study of macromolecules and macromolecular mechanisms that has an appearance in living organisms is called molecular biotechnology. The main objective of Molecular Biotechnology is to focus on the structure and function of the gene, the nature of the gene, gene replication, gene expressions and mutations. The concept of Molecular Biotechnology was introduced in the 1930s and 1940s and was not only imminent in the early stages of its introduction but gained importance in the 1950s and 1960s. The use of biotechnology Molecular was made by geneticists, structural chemists and physicists. Francis Crick introduced himself as a molecular biologist and further described as "a mixture of a crystallographer".
This implies more room for manufacture for different types of research and analysis. The different types of research involved are immunology, microbiology, genetics, cell biology and molecular biology. The importance of molecular biotechnology is becoming an imminent process in the field of agriculture. The main objective of Molecular Biotechnology is to understand the different biological processes involved and the creation of sensitive products.
- Track 5-1Translational Genomics
- Track 5-2Virus-Cell Interaction
- Track 5-3Computational Metagenomics
- Track 5-4Molecular Medicine and Pathology
- Track 5-5Genetic Engineering
- Track 5-6Cell & Gene Therapy
- Track 5-7Molecular Immunology
- Track 5-8Clinical Genetics
- Track 5-9Pharmacogenetics
- Track 5-10Molecular Genetic Pathology
- Track 5-11Gene Mapping
- Track 5-12Computational Genomics
- Track 5-13Genetic Transformation
- Track 5-14Genetic Screening
- Track 5-15Regulation of Gene Expression
- Track 5-16Genetic Transplantation
- Track 5-17Artificial Biology
- Track 5-18Synthetic and Structural Vaccinology
- Track 5-19Biomarkers
- Track 5-20Molecular Biology
- Track 5-21Integrative biology
- Track 5-22Transcriptional neurobiology
- Track 5-23Molecular and Microbial Genetics
- Track 5-24Microbes and medicine
- Track 5-25Applied and Environmental Microbiology
- Track 5-26Axonal neurobiology
- Track 5-27Neuro-Epigenetics
- Track 5-28Stem cells and regenerative medicine
- Track 5-29Molecular Neuropathology
- Track 5-30Molecular Virology
- Track 5-31Developmental Neurobiology
- Track 5-32Molecular Cancer Genetics (LMCG)
- Track 5-33Computational Oncology
- Track 5-34RNA Biology and Biotechnology
- Track 5-35Cytogenetics
Medical biotechnology is the use of living cells and cellular materials for the research and production of pharmaceutical and diagnostic products that help to treat and prevent human diseases. Most medical biotechnologists work in academic or industrial settings. In university laboratories, these professionals conduct experiments in the framework of medical research studies; Industrial biotechnologists work on the development of drugs or vaccines. The field of medical biotechnology has made it possible to market microbial pesticides, insect resistant crops and environmental cleaning techniques.
Examples of discoveries in the field of medical biotechnology include insulin and growth hormone. The two discoveries were the result of research related to deoxyribonucleic acid (DNA). Many scientists in the field of medical biotechnology are studying genetic engineering. This involves the isolation, identification and sequencing of human genes to determine their functions. Working in this arena may eventually lead to remedies for certain diseases, such as Parkinson's disease and Alzheimer's syndrome.
- Track 6-1Infectious diseases
- Track 6-2Chronic diseases
- Track 6-3Vaccines and diagnostics
- Track 6-4Human genetics and genome analysis
- Track 6-5Stem cell research
- Track 6-6Regenerative medicine
- Track 6-7Biodesign
- Track 6-8Bioengineering
- Track 6-9Stem Cell Biology
Agents that is capable of acting against infection, by inhibiting the spread of an infectious agent or by killing the infectious agent outright, is known as anti-infective agent. Anti-infective is a general term that involves antifungals, antibiotics, anti-bacterial, anti-protozoans and antivirals.
The primary goal of final pharmaceutical product is Quality and Safety. Active Pharmaceutical Ingredients (API’s), used as ingredients in sterile medicinal products, must be sterile unless the final dosage form is terminally sterilized, or produced by a process including a sterilising filtration step. API’s intended for use in parenteral products must also comply with relevant specifications on bacterial endotoxins or pyrogens.
The manufacture of sterile API’s must be strictly controlled in order to reduce the risk of contamination with micro-organisms, endotoxins and particles. If the final dosage form is not to be sterilised by filtration, the API’s should be practically free of particles.
- Track 7-1Clinical research
- Track 7-2penicillins
- Track 7-3Antituberculosis agents
- Track 7-4Antimalarial agents
- Track 7-5Antifungals
- Track 7-6Anthelmintics
- Track 7-7Aminoglycosides
- Track 7-8Amebicides
- Track 7-9Anti-Infectives Drug Discovery
- Track 7-10Histoplasma capsulatum
In the areas of medicine, biotechnology and pharmacology, drug discovery is the process by which new drug candidates are discovered. Historically, drugs have been discovered by identifying the active ingredient from traditional remedies or by fortuitous discovery. Subsequent chemical libraries of small synthetic molecules, natural products or extracts have been screened in intact cells or whole organisms to identify substances that have a desirable therapeutic effect in a process known as conventional pharmacology. Since the sequencing of the human genome has allowed for the rapid cloning and synthesis of large amounts of purified proteins, it has become common to use high throughput screening of large compound libraries against isolated biological targets that are assumed to be a modification Of the disease in a process known as reverse pharmacology. The results of these screens are then tested in cells and then in animals for efficacy.
Drug development is the process of introducing a new pharmaceutical drug to the market once a lead compound has been identified by the drug discovery process. It includes pre-clinical research on micro-organisms and animals, the filing of regulatory status, such as through the US Food and Drug Administration for a new experimental drug to launch clinical trials on Humans and may include the step of getting regulatory approval with a new Drug to market the drug.
- Track 9-1Drug targets
- Track 9-2 Recent Advances in Spectroscopy
- Track 9-3Proteomics Drug Discovery
- Track 9-4Pharmaceutical Research & Development
- Track 9-5Computational chemistry
- Track 9-6Advanced Trends in Medicinal Chemistry in drug discovery and designing
- Track 9-7Insilco Drug Discovery
- Track 9-8Innovative Drug Discovery and Nanotechnology
- Track 9-9Novel Detection Technologies and Drug Discovery
- Track 9-10Novel Therapeutic approaches in treating Ocular Diseases
- Track 9-11Drug Quality Control
- Track 9-12Antibody Research
- Track 9-13Immunotherapy
- Track 9-14Screening and design
- Track 9-15Pharmaceutical drugs
- Track 9-16Clinical Research
- Track 9-17Clinical Trials
- Track 9-18Orphan Drugs
- Track 9-19 Pre-clinical research
- Track 9-20Drug Designing
- Track 9-21Perspective In Drug Discovery
- Track 9-22Computer Aided Drug Design (CADD)
- Track 9-23Biomarkers in Drug Discovery & Development
- Track 9-24Pharmacovigilance
Antibiotics are a type of antimicrobials that are used in treatment and prevention of bacterial infections. They may kill or inhibit the growth of bacteria. Many antibiotics are also effective against protozoans and fungi; some are toxic to humans and animals also, even when given in therapeutic dosage. Antibiotics are not effective against viruses such as common cold or influenza, and may be harmful when taken inappropriately. Physicians must ensure the patient has a bacterial infection before prescribing antibiotics. Antibiotic resistance invoke especially to the resistance to antibiotics that occurs in common bacteria that cause infection. The easy approach and capability of Antibiotics led to overuse in live-stock raising promotes bacteria to flourish resistance. This led to comprehensive problems with antibiotic resistance.
Antimicrobial stewardship is a coordinated program that promotes the appropriate use of antimicrobials (including antibiotics), improves outcomes for patients, reduces microbial resistance, and reduces the spread of infections caused by multidrug resistant organisms.
The abuse of antimicrobials is one of the most pressing public health problems in the world. Infectious organisms adapt to antimicrobials designed to kill them, making medicines ineffective. People infected with antimicrobial resistant organisms are more likely to have longer and more expensive hospital stays and may be more likely to die as a result of infection.
- Track 10-1Antimicrobials
- Track 10-2Research and development
- Track 10-3Antimicrobial Activity
- Track 10-4Antimicrobial Resistance & Infection Control
Biomedical engineering (BME) is the application of engineering principles and design concepts to medicine and biology for healthcare purposes (e.g. diagnostic or therapeutic). This field seeks to close the gap between engineering and medicine, combining the design and problem solving skills of engineering with medical and biological sciences to advance health care treatment, including diagnosis, monitoring, and therapy. Biomedical engineering has only recently emerged as its own study, compared to many other engineering fields. Such an evolution is common as a new field transitions from being an interdisciplinary specialization among already-established fields, to being considered a field in itself. Much of the work in biomedical engineering consists of research and development, spanning a broad array of subfields. Prominent biomedical engineering applications include the development of biocompatible prostheses, various diagnostic and therapeutic medical devices ranging from clinical equipment to micro-implants, common imaging equipment such as MRIs and EEGs, regenerative tissue growth, pharmaceutical drugs and therapeutic biological.
- Track 11-1 Biocompatible prostheses
- Track 11-2Clinical engineering
- Track 11-3Bionics
- Track 11-4Pharmaceutical engineering
- Track 11-5Neural engineering
- Track 11-6Genetic engineering
- Track 11-7Tissue engineering
- Track 11-8Biomedical optics
- Track 11-9Biomaterial
- Track 11-10Biomechanics
- Track 11-11Bioinformatics
- Track 11-12Therapeutic biologicals
- Track 11-13Pharmaceutical drugs
- Track 11-14Regenerative tissue growth
- Track 11-15 Medical devices
- Track 11-16Rehabilitation engineering
Clinical microbiology is a branch of medicine concerned with the prevention, diagnosis and treatment of infectious diseases caused by four kinds of microorganisms i.e. bacteria, fungi, parasites and viruses. In addition, this field of science studies various clinical applications of microbes for the improvement of health.
Rapid identification of microorganisms in the clinical microbiology laboratory can be of great value in selecting optimal patient management strategies for infections caused by bacteria, viruses, fungi, mycobacteria and parasites. Rapid identification of microorganisms in clinical specimens allows rapid de-escalation of broad spectrum agents to targeted antimicrobial therapy. Switching to appropriate therapy minimizes the risk of antibiotics, including disturbance of normal flora, toxic side effects and selective pressure. There is a critical need for new technologies in clinical microbiology, particularly for blood flow infections, the associated mortality among which is among the highest of all infections. It is equally important that the clinical laboratory community adopt laboratory experimental medicine practices and collaborate in translational research projects to establish clinical utility, cost-benefit and the impact of new technologies.
- Track 12-1Clinical Immunology
- Track 12-2Allergy
- Track 12-3Autoimmunity
- Track 12-4Cancer immunology and immunotherapy
- Track 12-5Inflammation
- Track 12-6Phagocytosis
- Track 12-7Immunotherapy and Vaccines
- Track 12-8Humoral Adaptive Immune System
- Track 12-9Immune System Development
- Track 12-10Transplantation
- Track 12-11Clonal Selection and Expansion
- Track 12-12Humoral Immune Effectors Functions
- Track 12-13Neutralization of antigen by secreted antibody
- Track 12-14Opsonization of Antigen
- Track 12-15Mucosal Immunity
- Track 12-16Antibody-dependent cell cytotoxicity (ADCC)
- Track 12-17Immediate hypersensitivity
- Track 12-18Neonatal Immunity
- Track 12-19Activation of the classical complement pathway
- Track 12-20Cell-mediated adaptive immune system
- Track 12-21Clinical Perspectives- Transplantation rejection
- Track 12-22Clinical Perspectives- Hypersensitivity
A biopharmaceutical product, also known as a biological (biological) or biological (biological) product, is any pharmaceutical drug product manufactured, extracted or semi-synthesized from biological sources. Different pharmaceutical products synthesized include vaccines, blood, blood components, allergens, somatic cells, gene therapies, tissues, recombinant therapeutic proteins and living cells used in cell therapy. Biological products can be composed of sugars, proteins or nucleic acids or complex combinations of these substances or may be living cells or tissues. They (or their precursors or components) are isolated from living sources - human, animal, plant, fungal or microbial.
The terminology surrounding biopharmaceuticals varies between groups and entities, with different terms referring to different subsets of therapeutics in the general biopharmaceutical category. Some regulators use the terms "biological drugs" or "therapeutic biologics" to refer specifically to macromolecular products manufactured such as protein and nucleic acid drugs, distinguishing them from products such as blood, blood components Or vaccines, Biological. Specialty drugs, a recent classification of pharmaceuticals, are high-priced drugs that are often biologics.
- Track 13-1Vaccines
- Track 13-2Generic drugs
- Track 13-3Biopharmaceutical Companies & Market Analysis
- Track 13-4Herbal Drug Interactions
- Track 13-5Interpenetrating Polymer Network as DDS
- Track 13-6Nanoparticles-An Innovative Drug Delivery System
- Track 13-7Protein Interactions as Targeted Therapeutics
- Track 13-8Regulatory Sciences
- Track 13-9Biowaiver
- Track 13-10Biological Medicine
- Track 13-11Biologic Drugs
- Track 13-12Array of Clinical Trials in Biopharmaceutics
- Track 13-13Applied Biopharmaceutics
- Track 13-14Xenobiotics
- Track 13-15recombinant DNA technology
- Track 13-16Biosimilars
- Track 13-17Gene therapy
- Track 13-18Biogenomic in emergency medicine
Cosmeceuticals refers to the combination of cosmetic and pharmaceutical products. Cosmeceuticals are cosmetic products with biologically active ingredients claiming to have medical or drug-like benefits.
Dermatological research suggests that the bioactive ingredients used in cosmeceuticals have benefits beyond the traditional moisturizer. However, despite reports of profits from some cosmeceutical products, there is no requirement to prove that these products live up to their claims.
The label "cosmeceutical" applies only to products applied locally, such as creams, lotions and ointments. Products that are similar in perceived benefits but ingested orally are known as nutricosmetics.
- Track 14-1Cosmetics and Pharmaceuticals
- Track 14-2Antioxidant
- Track 14-3 Clinical trials
Industrial and Microbial Biotechnology uses enzymes and micro-organisms to make bio based products in sectors such as chemicals, food and feed, detergents, paper and pulp, textiles and bioenergy (such as biofuels or biogas). In doing so, it uses renewable raw materials and is one of the most promising, innovative approaches towards lowering greenhouse gas emissions. The application of industrial biotechnology has been proven to make significant contributions towards mitigating the impacts of climate change in these and other sectors.
In addition to environmental benefits, biotechnology can improve industry’s performance and product value and, as the technology develops and matures, white biotechnology will yield more and more viable solutions for our environment. These innovative solutions bring added benefits for both our climate and our economy.
The rapid developments in biotechnology and the applications of genetic engineering to practical human problems have allowed the advancement of pharmaceutical biotechnology at a staggering pace. Furthermore, the release of the human genome sequence has also been key for the identification of human genetic diseases and the design of revolutionary approaches for their treatment.
Genetic engineering involves altering DNA molecules outside an organism, making the resultant DNA molecules function in living cells. Many of these cells have been genetically engineered to produce substances that are medically useful to humans.
Pharmaceutical biotechnology involves the use of living organisms such as microorganisms to create new pharmaceutical products, or safer and more effective versions of conventionally produced pharmaceuticals, more cost-effectively.
Since the manufacture of the first recombinant pharmaceutical, insulin, there has been a burst in the generation of new recombinant drugs, some of which will be covered later on in this chapter. Furthermore, the use of recombinant DNA technology has spread further allowing the development of not only subunit vaccines, such as the one used in the prevention of hepatitis B, but also attenuated vaccines vector vaccines and DNA vaccines. One of pharmaceutical biotechnology’s great potentials lies in gene therapy, which consists of the insertion of genetic material into cells to prevent, control or cure disease. It encompasses repairing or replacing defective genes and making tumours more susceptible to other kinds of treatment.
- Track 16-1Vaccines and Antibiotics
- Track 16-2Protein Engineering
- Track 16-3Biotechnology in Forensic Medicine
- Track 16-4Microarray Technology
- Track 16-5Clinical Research/Clinical Trials
- Track 16-6Personalized Medicine
- Track 16-7Biomarkers
- Track 16-8Biopharmaceutical Manufacturing and Diagnostics
- Track 16-9Downstream Processing of Biopharmaceuticals
- Track 16-10Technological and Clinical Aspects of Biopharmaceuticals
- Track 16-11Biopharmaceuticals Discovery
- Track 16-12Bioinformatics
Healthcare biotechnology refers to a medicinal or diagnostic product or a vaccine that consists of, or has been produced in, living organisms and may be manufactured via recombinant technology (recombinant DNA is a form of DNA that does not exist naturally. It is created by combining DNA sequences that would not normally occur together). This technology has a tremendous impact on meeting the needs of patients and their families as it not only encompasses medicines and diagnostics that are manufactured using a biotechnological process, but also gene and cell therapies and tissue engineered products. Biotechnology offers patients a variety of new solutions such as: Unique, targeted and personalized therapeutic and diagnostic solutions for particular diseases or illnesses, An unlimited amount of potentially safer products, Superior therapeutic and diagnostic approaches, Higher clinical effectiveness because of the biological basis of the disease being known, Development of vaccines for immunity, Treatment of diseases, Cultured Stem Cells and Bone Marrow Transplantation, Skin related ailments and use of cultured cell, Genetic Counseling, Forensic Medicine, Gene Probes, Genetic Fingerprinting, Karyotyping.
Biomanufacturing is a type of manufacturing or biotechnology that uses biological systems to produce biomaterials and biomolecules that are commercially important for drugs, food and beverage processing, and industrial applications. Organically produced products are recovered from natural sources, such as blood, or cultures of microbes, animal cells or plant cells grown in specialized equipment. The cells used during production may have been naturally produced or derivatives using genetic engineering techniques.
- Track 18-1Bio-fuels
- Track 18-2Energy Crops (cellulosic ethanol industry)
- Track 18-3Industrial Enzymes
- Track 18-4Bioprocess Engineering and Optimization
Regenerative medicine is a branch of translational research in tissue engineering and molecular biology which deals with the "process of replacing, engineering or regenerating human cells, tissues or organs to restore or establish normal function". This field holds the promise of engineering damaged tissues and organs by stimulating the body's own repair mechanisms to functionally heal previously irreparable tissues or organs.
Regenerative medicine also includes the possibility of growing tissues and organs in the laboratory and implanting them when the body cannot heal itself. If a regenerated organ's cells would be derived from the patient's own tissue or cells, this would potentially solve the problem of the shortage of organs available for donation, and the problem of organ transplant rejection.
Some of the biomedical approaches within the field of regenerative medicine may involve the use of stem cells. Examples include the injection of stem cells or progenitor cells obtained through directed differentiation (cell therapies); the induction of regeneration by biologically active molecules administered alone or as a secretion by infused cells (immunomodulation therapy); and transplantation of in vitro grown organs and tissues (tissue engineering).
- Track 19-1Stem Cells
- Track 19-2Gene Therapy
- Track 19-3Cell Based Therapy
- Track 19-4Tissue Engineering
- Track 19-5Cell Cultivation
- Track 19-6Clinical Research/Clinical trials
A biofuel is a fuel that is produced by contemporary biological processes, such as agriculture and anaerobic digestion, rather than a fuel produced by geological processes such as those involved in the formation of fossil fuels such as coal and Oil, from prehistoric biological material. Biofuels can come directly from plants, or indirectly from agricultural, commercial, domestic and / or industrial wastes. Renewable biofuels typically involve the fixation of contemporary carbon, such as those that occur in plants or microalgae through the process of photosynthesis. Other renewable biofuels are made from the use or conversion of biomass (referring to living organisms recently, most often referring to plants or plant-derived materials). This biomass can be converted into suitable energy substances in three different ways: thermal conversion, chemical conversion and biochemical conversion. This conversion of the biomass can result in a fuel in solid, liquid or gaseous form. This new biomass can also be used directly for biofuels.
Bioethanol is an alcohol obtained by fermentation, mainly from carbohydrates produced in sugar or starch cultures such as corn, sugar cane or sweet sorghum. Cellulosic biomass, derived from non-food sources, such as trees and grasses, is also developed as a raw material for ethanol production. Ethanol can be used as fuel for vehicles in its pure form, but it is usually used as an additive to increase octane and improve vehicle emissions. Bioethanol is widely used in the United States and Brazil. The current design of the facility does not convert the lignin portion of the plant raw materials into fuel components by fermentation.
Biodiesel can be used as a fuel for vehicles in its pure form, but is usually used as a diesel additive to reduce the levels of particulate matter, carbon monoxide and hydrocarbons in diesel vehicles. Biodiesel is produced from oils or fats by trans esterification and is the most common biofuel in Europe.
Biosafety is the prevention of large-scale loss of biological integrity, focusing both on ecology and human health. These prevention mechanisms include conduction of regular reviews of the biosafety in laboratory settings, as well as strict guidelines to follow. Biosafety is used to protect from harmful incidents. Many laboratories handling biohazards employ an on-going risk management assessment and enforcement process for biosafety. Failures to follow such protocols can lead to increased risk of exposure to biohazards or pathogens. Human error and poor technique contribute to unnecessary exposure and compromise the best safeguards set into place for protection.
Biosafety in agriculture, chemistry, medicine, exobiology and beyond will likely require the application of the precautionary principle, and a new definition focused on the biological nature of the threatened organism rather than the nature of the threat.
Bioethics is the study of the typically controversial ethical issues emerging from new situations and possibilities brought about by advances in biology and medicine. It is also moral discernment as it relates to medical policy and practice. Bioethicists are concerned with the ethical questions that arise in the relationships among life sciences, biotechnology, medicine, politics, law, and philosophy. It also includes the study of the more commonplace questions of values ("the ethics of the ordinary") which arise in primary care and other branches of medicine.
- Track 21-1Biosafety Regulations
- Track 21-2Intellectual Property Rights
- Track 21-3Ethical Issues of Human Genome Project
- Track 21-4Organs Transplantation and Stem Cell Research
- Track 21-5Handling and Disposal of Hazardous Materials
This session will provide the opportunity to hear “both sides of the story” from a non-sterile aqueous product contamination case. Speakers will present both industry and FDA perspectives from an actual product contamination event, and the path taken to resolve the problem. Attendees will discover how FDA and industry worked together to solve a microbial product issue, and the lessons learned from the case.
- Track 22-1Factors affecting choice of antimicrobial agent
- Track 22-2Properties of the chemical agent
- Track 22-3Mycobacterium tuberculosis
- Track 22-4Vegetative bacteria
- Track 22-5 Bacterial spores
- Track 22-6Toxicity of the agent
- Track 22-7Acids and esters
- Track 22-8Benzoic acid
- Track 22-9Sorbic acid
- Track 22-10Sulphur dioxide, sulphites and metabisulphites
- Track 22-11Esters of p-hydroxybenzoic acid (parabens)
- Track 22-12Alcohols used for disinfection and antisepsis
- Track 22-13Alcohols as preservatives
- Track 22-14Aldehydes
- Track 22-15Glutaraldehyde
- Track 22-16Ortho-phthalaldehyde
- Track 22-17Formaldehyde
- Track 22-18Formaldehyde-releasing agents
- Track 22-19Chlorhexidine and alexidine
- Track 22-20Polyhexamethylene biguanides
- Track 22-21Halogens
- Track 22-22Hypochlorites
- Track 22-23Organic chlorine compounds
- Track 22-24Chloroform
- Track 22-25Iodine
- Track 22-26Iodophors
- Track 22-27Heavy metals
- Track 22-28Mercurials
- Track 22-29Hydrogen peroxide and peroxygen compounds
- Track 22-30Phenols
- Track 22-31Phenol (carbolic acid)
- Track 22-32 Clear soluble fluids, black fluids and white fluids
- Track 22-33Synthetic phenols
- Track 22-34 Bisphenols
- Track 22-35 Surface-active agents
- Track 22-36Cationic surface-active agents
- Track 22-37Diamidines
- Track 22-38Dyes
- Track 22-39Quinoline derivatives
- Track 22-40Antimicrobial combinations and systems
- Track 22-41Disinfection policies
Due to multidisciplinary nature of the field of biotechnology, a wide range of different branches of science have made significant contributions to the fast development of this field. Some of these discipline are- biochemical engineering, physiology, biochemistry, food science, material science, bioinformatics, immunology, molecular biology, chemical engineering etc. Biotechnology is also improving the lives of people around the world. Biotechnology also has affected economy in a positive way due to the creation and growth of small business, generation of new jobs. Agricultural biotechnology has reduced our dependency on pesticides. Bioremediation technologies are being used to clean our environment by removing toxic substances from contaminated ground water and soils. about 60% of the biotechnology products in the market are healthcare products and 21% are products used in agriculture and animal husbandry. A considerable amount of efforts in research are on, to use and extract benefit from this interesting and upcoming field for the betterment of human life and the environment. Many biochemical companies are involved in the production of biotechnological products using genetic engineering techniques
- Track 23-1Ruminant Nutrition
- Track 23-2Cancer therapy by Immunogenic Oligopeptide
- Track 23-3Reproductive Medicine
- Track 23-4Urology
- Track 23-5Biotechnology for Biofuels
- Track 23-6Nutritional approach vs Alzheimer’s disease
The method by which a drug is delivered can have a significant effect on its efficacy. Some drugs have an optimum concentration range within which maximum benefit is derived, and concentrations above or below this range can be toxic or produce no therapeutic benefit at all. On the other hand, the very slow progress in the efficacy of the treatment of severe diseases, has suggested a growing need for a multidisciplinary approach to the delivery of therapeutics to targets in tissues. From this, new ideas on controlling the pharmacokinetics, pharmacodynamics, non-specific toxicity, immunogenicity, biorecognition, and efficacy of drugs were generated. These new strategies, often called drug delivery systems (DDS), are based on interdisciplinary approaches that combine polymer science, pharmaceutics, bioconjugate chemistry, and molecular biology.
- Track 24-1Pre-Formulation & Formulation Aspects
- Track 24-2 Peptides and Protein Drug Delivery
- Track 24-3Medical Devices for Drug Delivery
- Track 24-4Vaccine Drug Delivery Systems
- Track 24-5Biomaterials in Drug Delivery
- Track 24-6Smart Drug Delivery Systems
- Track 24-7Pharmaceutical Nanotechnology
- Track 24-8Nanotechnology in Drug Delivery
- Track 24-9Nanoparticulate Drug Delivery Systems
- Track 24-10Routes of Drug Delivery
- Track 24-11Drug Targeting and Design
- Track 24-12Pharmacokinetics and Pharmacodynamics in Drugs
- Track 24-13Global Drug Delivery Policy
Nanomedicine can be defined as medical application of nanotechnology. Nanomedicine ranges from the medical applications of nanomaterials and biological devices, Nano electronic devices &biosensors and possible future applications of molecular nanotechnology. Nanomaterials can be functionalised to interface with biological molecules & structures as the size of nanomaterials is comparable to most biological molecules and structures. Nanomaterials can be useful for both in vivo and in vitro biomedical research and applications and integration of nanomaterials with biology has led to the development of advanced diagnostic devices, physical therapy applications, analytical tools, contrast agents and drug delivery vehicles. Nanomedicine strives for delivering valuable set of research tools & clinically useful devices and its industry sales reached $16 billion in 2015, with an average of $3.8 billion investment in nanotechnology R&D every year and increase of 45% per year global funding for emerging nanotechnology
- Track 25-1Nanotechnology in Healthcare
- Track 25-2Biomaterials and Medical Devices
- Track 25-3Nanomaterials and Nanotechnology
- Track 25-4Nano Composites and Multiscale Nano materials
- Track 25-5Advanced Characterization of Nanomaterials
- Track 25-6Graphene modification and functionalization
- Track 25-7Nano in Pharmaceutical Chemistry
- Track 25-8Nanomedicine in Drug Delivery Systems
- Track 25-9Nanotechnology for Environment and Nano safety
- Track 25-10Applications of Nanotechnology in Health Care
- Track 25-11Nano medicine and Nano pharmaceuticals
- Track 25-12Future prospects of Nanotechnologies and commercial viability
Biotherapeutics usually refers to therapeutic materials produced using biological means, including recombinant DNA technology. Biotherapeutics are basically agents, used to treat and avoid human disease by interrelating with the microbial ecology of the host. Biotherapeutics have the ability to target specific molecules within the human body, and have a good track record with patient safety. Manufacturing biotherapeutics is complex, as they are larger compounds in both size and structure, and can be sensitive to environmental conditions. Additionally, Biotherapeutic manufacturing includes many regulations such as signal processing, biology and engineering process control. Moreover, they require sophisticated production and control processes and are dependent upon the host cells of living organisms to produce the necessary active pharmaceutical substances.
- Track 26-1Advancements in Biotherapeutics
- Track 26-2Bioanalytical Techniques
- Track 26-3Drug Metabolism Studies
- Track 26-4Drug Analysis
- Track 26-5Structural Analysis of Small Organic Molecules
- Track 26-6Analytical Biotherapeutics
- Track 26-7 Biotherapy
- Track 26-8Clinical Biotherapeutics
- Track 26-9 Cancer Biotherapeutics
- Track 26-10Stem Cell Therapy
- Track 26-11Innovative Therapies for Serious Diseases
- Track 26-12Immunopharmacotherapy
- Track 26-13Oncolytic Virotherapy
- Track 26-14MicroRNAs (miRNAs) Biotherapeutics
- Track 26-15Synthetic Immunology
- Track 26-16Chromatographic Techniques
- Track 27-1Strategic Alliances
- Track 27-2Venture Capital and Financing
- Track 27-3Outsourcing
- Track 27-4Merger and Acquisitions
- Track 27-5Licensing
- Track 27-6Growth
- Track 27-7Business Models and Strategies
- Track 27-8Product Opportunities
- Track 27-9Partnering Trends
- Track 27-10Intellectual Property